key: cord-0895347-dxk0rcgi
authors: Do, Mytrang H.; Stewart, Claire R.; Harp, Joanna
title: Cutaneous Manifestations of COVID-19 in the Inpatient Setting
date: 2021-05-28
journal: Dermatol Clin
DOI: 10.1016/j.det.2021.05.011
sha: b09138ac1b433c9322217294eb693b4ef1a858a9
doc_id: 895347
cord_uid: dxk0rcgi

Cutaneous findings have increasingly been reported in patients with coronavirus disease 2019 (COVID-19). This review discusses associated skin findings in COVID-19 patients in the inpatient setting, ranging from vasculopathy-related lesions associated with high hospitalization rate and poor prognosis to inflammatory vesicular and urticarial eruptions that are rarely associated with prolonged hospitalization. We also discuss other reported COVID-19 cutaneous manifestations such as Sweet's syndrome, purpuric eruptions, and Multisystem Inflammatory Syndrome in Children (MIS-C). While the relationship between dermatological changes and COVID-19 disease progression is not fully elucidated, familiarity with cutaneous manifestations is valuable for physicians caring for hospitalized COVID-19 patients and may help improve disease recognition and care.

Since December 2019, coronavirus disease 2019 (COVID-19) has spread globally and caused significant morbidity and mortality worldwide. Cutaneous manifestations have been observed in COVID-19 patients with varying prevalence ranging from 0.2% to 24%. 1-4 However, the true prevalence of cutaneous lesions is difficult to assess. Many studies included patients with both suspected and confirmed cases of COVID-19, and the lack of adequate personal protective equipment, especially at the beginning of the pandemic, may have precluded a thorough skin examination in many patients. A recent publication showed that 35/396 patients (11.8%) of hospitalized COVID-19 patients had dermatologic findings. 5 Similar to the heterogeneity of systemic symptoms of COVID-19, cutaneous manifestations of COVID-19 are wide-ranging. In addition to varying morphologies, the eruptions affect disparate age groups and exhibit varying time courses; while some portend serious disease, others are associated with milder illness. 6, 7 Certain dermatologic conditions are more prevalent in the inpatient compared to outpatient setting-an important distinction when reviewing the mucocutaneous eruptions associated with COVID-19. 5 It is believed that the varying clinical manifestations are due to patients' differing immune response to the Severe Acute Respiratory Syndrome

Livedo reticularis is characterized by nonfixed, dusky patches forming complete rings, reflecting the underlying dermal and subcutaneous vasculature, and is caused by partial or intermittent blood flow reduction to the skin. 16 Livedo reticularis was observed in 5.3% of confirmed COVID-19 patients with dermatologic manifestations included in the American Academy of Dermatology's (AAD) COVID-19 registry. 6 However, livedo reticularis was not reported in several other case series that included large numbers of patients 1, 3, 4 (Table 1) . Given the scarcity of this morphology, full clinical characterization of livedo reticularis in COVID-19 patients is not currently possible. However, cases of fluctuating or transient livedo reticularis on the trunk and thigh have been reported. 17, 18 Pauci-inflammatory thrombotic vasculopathy was seen in a biopsy of livedo reticularis. 6 Most reported cases were mild, not associated with thromboembolic complications, and resolved without dermatological treatment; however, one death was reported in a patient with livedo reticularis. 6 The presence of microthromboses or low-grade vascular inflammation and vasodilation resulting from endothelial cell damage due to SARS-CoV-2 infection has been proposed as an etiology. 17, 18 2. Livedo racemosa/retiform purpura/cutaneous necrosis Livedo racemosa presents with persistent erythematous to violaceous broken rings that are rarely necrotic or ulcerative, indicating a significant reduction in blood flow to the skin ( Figure 1 ). Livedo racemosa was observed in 2.3% COVID-19 confirmed patients in the AAD's COVID-19 registry. 6 Retiform purpura exists on a spectrum with livedo racemosa but is a more severe variant caused by full blockage of cutaneous blood flow leading to persistent purpuric and reticular patches or plaques with frank or impending J o u r n a l P r e -p r o o f necrosis and/or ulceration ( Figure 2 ). 16 Retiform purpura was observed in 6.4% COVID-19 confirmed patients in the AAD's COVID-19 registry and in 9/35 (25.7%) of hospitalized COVID-19 patients who developed dermatologic findings. 5, 6 Galvan-Casas et al. observed livedo (type not specified) and necrosis in 6% of suspected and confirmed COVID-19 patients 7 (Table 1) . Patients who developed retiform purpura were older, with a median age of 66 years, and sicker, with 91% requiring mechanical ventilation and 82% developing acute respiratory distress syndrome (ARDS). 6, 7 Systemic thrombotic events such as deep venous thrombosis or pulmonary embolism occurred in 66% of the patients. With a 10-18% mortality rate, livedo racemosa and retiform purpura were among the highest mortality of COVID-19associated cutaneous manifestations. 6, 7 Livedoid and necrotic skin lesions were also reported in case reports and case series with similarly poor prognosis. [19] [20] [21] [22] Patients had varying degrees of alterations in coagulation parameters, most notably elevated d-dimer, and many also had systemic thromboembolic complications. While disseminated intravascular coagulation (DIC) has been implicated in COVID-19 patients, some patients with livedo racemosa or retiform purpura did not develop classic DIC laboratory parameters. 21,23,24 The presence of antiphospholipid antibodies was variable, as some COVID-19 patients with acroischemia were found to have antiphospholipid antibodies though others did not. 19, 20, 22 Nevertheless, antiphospholipid antibodies can arise transiently in patients with critical illness and infection. 25 It is rare for these findings to precede the onset of COVID-19 symptoms. Freeman et al. showed that livedo (type not specified) and necrosis paralleled the onset of COVID-19 symptoms (86%). Given that the constellation of COVID-19 symptoms was not wellcharacterized early during the pandemic, this discrepancy may reflect differences in perception of symptom onset by clinicians and patients. Livedoid eruptions occur more often on the acral areas and last approximately 10 days, whereas retiform purpura has been described on the extremities and the buttocks. While a pressure component may contribute to the development of retiform purpura, these lesions were also present in patients who were intermittently proned. 26,27 Many patients were started on therapeutic anticoagulation during their hospital course due to increasing d-dimer and suspected or confirmed thrombotic events. 20,28 Although anticoagulation in severe cases of has been shown to reduce mortality, both the exact dosing and the timing of anticoagulation initiation in these patients remain to be determined. 29, 30 It is critical to consider the overall clinical picture and the patient's comorbidities, particularly bleeding risk, when determining the best course of treatment.

The pathophysiology of this coagulopathy is an area of active research. Complementmediated microvascular injury appears to play an essential role in some cases.

Exaggerated complement activation has been implicated in severe COVID-19. 9,10 As the complement system links innate immunity to coagulation, 31 its overactivation could promote a thrombotic state in patients with severe COVID-19. Skin biopsies from patients with livedo racemosa and retiform purpura showed a pauci-inflammatory thrombogenic vasculopathy affecting capillaries, venules, and arteries with microvascular deposition of C3d, C4d, C5b-9, and MASP-2. 12,13,20 Excessive J o u r n a l P r e -p r o o f inflammation caused by a cytokine storm and the subsequent recruitment of immune cells has also been proposed as a potential cause of thrombophilic states in these patients. 32

Critically ill hospitalized patients, including COVID-19 patients, are at an increased risk for sacral/buttock ulcerations caused by hospital-acquired pressure injuries (Table 1) .

Ulcers described were often covered with black eschar with surrounding erythema and violaceous discoloration. 33 Livedoid plaques and retiform purpura, with biopsy showing thrombotic vasculopathy and evidence of pressure necrosis, were noted in some patients ( Figure 3 ). 12,33 Notably, COVID-19 patients were found to develop these lesions earlier than other patient populations.

Additionally, acrofacial purpura and necrosis associated with minor pressure injuries due to direct contact with medical devices such as nasal cannulas, endotracheal tubes, or pulse oximeters has been reported in COVID-19 patients. 26,27 Importantly, given that many COVID-19 patients are placed in a prone position to improve oxygenation status, pressure-associated ulceration and necrosis can occur in a unique distribution such as the bilateral cheeks compared to the usual locations such as the sacrum and heels. As ulcerations can serve as portals of entry for microbes leading to infection, it is critical to monitor patients closely to prevent additional morbidity and mortality. Patients may also present with conjunctival injection, palmoplantar erythema, periorbital erythema and edema, and strawberry tongue, which is notably similar to the mucocutaneous exam in patients with KD, necessitating a high index of suspicion for COVID-19 induced MIS-C in these patients.

While COVID-19 infection in children is generally associated with a mild course with minimal or no symptoms, up to 68% of children with MIS-C required admission to a J o u r n a l P r e -p r o o f critical care unit, and 15% required ventilation 39 (Table 1 ). In a prospective study of pediatric patients hospitalized with acute SARS-CoV-2 and MIS-C, lower absolute lymphocyte count and higher C-reactive protein were predictive of more severe MIS-C. 40 While race/ethnicity were not predictive of disease severity, more than 75% of the (Table 1) .

Hospitalization rates for patients with morbilliform eruptions ranged from 45% to 80%, higher than the 30% to 38% seen in COVID-19 patients with non-morbilliform cutaneous manifestations. 6, 7 Morbilliform eruptions were shown to occur in 4/35 (11.4%) of hospitalized COVID-19 patients who developed dermatologic findings. 5

In both hospitalized and non-hospitalized patients, eruptions can occur concurrently or after other COVID-19 symptoms and last for an average of one week. 6, 44, 45 Truncal regions were the most commonly affected areas, followed by extremities. The most commonly reported symptom was pruritis. Patients who developed morbilliform eruptions were often in their fifties and sixties. 6, 44, 45 The overall rate for thrombotic events was 8% and for ARDS was 11%; 35% required ventilator support. The overall mortality of COVID-19 patients who developed morbilliform eruptions ranged from 2.6% 

Urticarial eruptions are transient erythematous and edematous plaques of varying sizes mediated by mast cell histamine release in the superficial dermis. 52 Urticarial eruptions account for 13.5%-26% of cases of COVID-19 cutaneous manifestations 1,3,4,6,7 (Table   1) . Hospitalization rates were 33%-44%, similar to COVID-19 patients with nonurticarial cutaneous manifestations (34%-48%). 6 

In a large cohort study, 7.2% of patients presenting with COVID-19-associated cutaneous manifestations were reported to have a vesicular eruption 5 (Table 1) . Two vesicular forms have been documented: a localized, monomorphic form found on the trunk and limbs and a diffuse, polymorphic form. 7, 62 Most patients report minimal itching, which may help distinguish this eruption from the often very pruritic eruption of varicella. 63, 64 Vesicular lesions associated with COVID-19 are most commonly seen in middle-aged men, with an average age of 45.6 ± 20 years. 6 The eruption is believed to be associated with early infection. The average latency time from onset of symptoms to rash is only 3 days (range -2-12 days); 15% of patients present with the lesions before any other COVID-19 symptoms. 6, 45 In a cohort of Spanish patients, 32% with vesicular eruptions were admitted to a hospital, though only 6% required intensive care. 6 In a study comparing 24 COVID-19 patients with vesicular eruptions, of 6 patients with the localized pattern, 83.3% had concomitant COVID-19 pneumonia, compared to only 27.8% of those with the 18 patients who presented with the diffuse pattern; however, this was not statistically significant, likely due to small sample size. 62 Further research is required to fully elucidate the differences in the vesicular eruptions of those with severe COVID-19 requiring hospitalization compared to those with milder or asymptomatic disease. Lesions resolved in an average of 8-10 days without scarring. 62, 64 It has been proposed that the direct pathogenic effect of the SARS-CoV-2 virus on basal layer keratinocytes may lead to acantholysis and dyskeratosis. 63 To date, there has not been a report of the SARS-CoV-2 virus inside vesicles, identified by PCR assay or other methods, indicating that the infective potential via vesicles is likely minimal.

In April, a new pattern of erythema multiforme (EM)-like lesions in four adults hospitalized with COVID-19 was first described; since then, there have been numerous reports of EM-like lesions in children and young adults associated with SARS-CoV-2 infection 65 (Table 1) . Lesions appear as erythematous macules, papules, and plaques with crusted centers consisting of two (atypical targets) or three (typical targets) rings often observed on the extremities. . [65] [66] [67] Lesions may be pruritic or painful. 51 Some patients present with oral mucosal involvement, including palatal macules and petechiae, and erosive cheilitis. 68, 69 The mean age of patients with EM-like eruptions is 12.2 years with a male predominance (59.5%). 45 Latency of EM-life eruptions has been reported to range from only a few days to three weeks after the onset of initial COVID-J o u r n a l P r e -p r o o f described in up to 3.7% of patients hospitalized with COVID-19. 45 Of note, the incidence of EM-like eruptions may be under-reported as some studies group unspecific rashes of annular appearance into an "other rash" category. 70 Many patients were treated with systemic corticosteroids with the resolution of lesions. 71 The pathogenesis of EM-like eruptions is not fully understood. Still, it is likely viral in etiology, though exposure to certain medications received in the treatment of other COVID-19 symptoms may play a role.

Patients

Sweet's syndrome, also known as acute febrile neutrophilic dermatosis, is a nonvasculitic sterile neutrophilic dermatosis syndrome often presenting with fever, arthralgias, and neutrophilia. Sweet's syndrome may be idiopathic, malignancyassociated, or drug-induced, and cases associated with viral infections have been reported. 72 There exists at least one case of a patient hospitalized with COVID-19 who developed Sweet's syndrome 73 

Many cases of pernio or pernio-like lesions (red-purple tender papules typically affecting toes and fingers) have been reported typically as a late manifestation of confirmed or suspected COVID-19 infection. While "COVID toe" is typically noted in young, healthy patients with mild or even asymptomatic COVID-19 infections, 16% of patients with "COVID toe" in one large international registry were hospitalized. 5 It should be noted however, that misclassification of acral livedo or retiform purpura as "COVID toe" could occur given similar presenting locations and some overlap clinically (both present with purpura) especially if being evaluated and classified by non-dermatologists. In one J o u r n a l P r e -p r o o f the inpatient setting of a large, academic hospital setting in New York City throughout the pandemic.

Adults and children hospitalized with COVID-19 display a range of mucocutaneous eruptions, the diversity of which is likely due to the varying immune response generated in response to SARS-CoV-2 infection. In the hospitalized patient, livedo racemosa and retiform purpura were associated with more severe disease course, poorer prognosis, prolonged hospitalization and higher mortality. In contrast, most viral exanthem and inflammatory lesions, such as urticarial and vesicular eruptions, were associated with a less severe COVID-19 disease course, though were nevertheless reported more frequently in the inpatient setting. One exception, however, is the presence of an inflammatory rash associated with MIS-C in the inpatient pediatric population which has been associated with more severe COVID-19 disease and disease sequelae. Prompt recognition of the mucocutaneous manifestations presented in this article is paramount to facilitate timely diagnosis, proper treatment and accurate prognostication of clinical course. 

Cutaneous manifestations in COVID-19: a first perspective

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Cutaneous manifestations in hospitalized patients diagnosed as COVID-19

Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy

Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19

The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries

The differing pathophysiologies that underlie COVID-19 associated perniosis and thrombotic retiform purpura: a case series

Cutaneous manifestations in COVID-19: Lessons learned from current evidence

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

Retiform purpura: A diagnostic approach

A dermatologic manifestation of COVID-19: Transient 49

Microthrombi in skin biopsy of a patient with COVID-19

Clinical and histological characterization of late appearance maculopapular eruptions in association with the coronavirus disease 2019. A case series of seven patients

Exanthema and eosinophilia in COVID-19 patients: has viral infection a role in drug induced exanthemas?

Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases

Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients

Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms

Urticaria in the times of COVID-19

Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital

Histology of skin lesions establishes that the vesicular rash associated with COVID-19 is not 'varicella-like

Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients

Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings

Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2

Acral purpuric lesions (erythema multiforme type) associated with thrombotic vasculopathy in a child during the COVID-19 pandemic

Cutaneous and histopathological features of coronavirus disease 2019 in pediatrics: A review article

Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children

Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France

Erythema multiforme-like lesions in children and COVID-19

Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis

Coronavirus 19 presenting with atypical Sweet's syndrome

Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19

COVID-19-associated immune thrombocytopenia

Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series

COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature

Immune Thrombocytopenic Purpura in a Patient with Covid-19

A rare case of immune thrombocytopenic purpura, secondary to COVID-19

Mechanism of thrombocytopenia in COVID-19 patients

Thrombocytopenia and its association with mortality in patients with COVID-19

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Figure 2 Early retiform purpura on the right foot in a patient with COVID-19 complicated by ARDS and ischemic stroke. Biopsy revealed pauci-inflammatory thrombotic vasculopathy

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Figure 3 Inflammatory retiform purpura in a COVID-19 patient complicated by ARDS. Biopsy revealed thrombotic From Magro C